MENU
+Compare
ARQT
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$13.27
Change
-$0.36 (-2.64%)
Capitalization
1.55B

ARQT Arcutis Biotherapeutics Forecast, Technical & Fundamental Analysis

a company, which engages in the development and commercialization of treatments for dermatological diseases.

Industry Biotechnology
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ARQT with price predictions
Jan 08, 2025

Aroon Indicator for ARQT shows an upward move is likely

ARQT's Aroon Indicator triggered a bullish signal on January 02, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator showed a similar pattern. In of the 161 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on ARQT as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ARQT moved out of overbought territory on January 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where ARQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ARQT turned negative on December 30, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARQT broke above its upper Bollinger Band on January 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.921) is normal, around the industry mean (15.212). P/E Ratio (0.000) is within average values for comparable stocks, (87.972). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.839). ARQT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (11.198) is also within normal values, averaging (258.672).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ARQT is expected to report earnings to fall 14.55% to -28 cents per share on March 04

Arcutis Biotherapeutics ARQT Stock Earnings Reports
Q4'24
Est.
$-0.28
Q3'24
Beat
by $0.09
Q2'24
Beat
by $0.09
Q1'24
Beat
by $0.37
Q4'23
Beat
by $0.06
The last earnings report on November 06 showed earnings per share of -33 cents, beating the estimate of -41 cents. With 1.84M shares outstanding, the current market capitalization sits at 1.55B.
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of treatments for dermatological diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3027 Townsgate Road
Phone
+1 805 418-5006
Employees
296
Web
https://www.arcutis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HJIGX12.070.09
+0.75%
Hardman Johnston Intl Gr Fd Instl Shr
ECOAX8.510.06
+0.71%
Ecofin Global Renewables Infras A
TROSX12.440.06
+0.48%
T. Rowe Price Overseas Stock
PSICX42.250.05
+0.12%
PGIM Quant Solutions Large-Cap Index C
TDEIX29.86-0.08
-0.27%
Transamerica US Growth I

ARQT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with BEAM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
-2.57%
BEAM - ARQT
39%
Loosely correlated
-8.77%
OCUL - ARQT
38%
Loosely correlated
-3.20%
TRDA - ARQT
36%
Loosely correlated
-6.58%
SANA - ARQT
35%
Loosely correlated
+4.91%
RYTM - ARQT
35%
Loosely correlated
-1.73%
More